Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Laurent Chanroux
  • December 7, 2016
  • Events

ACR conference 2016

ACR conference 2016

We were delighted to be chosen to present two posters at this year’s ACR conference in Washington on November  11-16. The posters, which are entitled, ‘A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies’ and ‘Patient Adherence with Biologic Therapy in RA’ are authored by Research Director Laurent Chanroux.

read more »

  • Posted by Laurent Chanroux
  • November 7, 2016
  • Events

Therapy Watch to present “real-world” patient data at Rheumatology ACR conference in Washington on November 11-16

Therapy Watch to present “real-world” patient data at Rheumatology ACR conference in Washington on November  11-16

We are delighted to have been chosen to present two posters at this year’s ACR conference in Washington on November  11-16. The posters, which are entitled, ‘A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies’ and ‘Patient Adherence with Biologic Therapy in RA’ are authored by Research Director Laurent Chanroux.

read more »

  • Posted by Julie Denny
  • May 26, 2016
  • Events

EULAR Annual European Congress of Rheumatology 2016

EULAR Annual European Congress of Rheumatology 2016

8-11 June 2016, London

Research Partnership is delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Since its introduction in 2000, the congress has become the primary platform for exchange of scientific and clinical information in Europe. With more than 16,000 delegates from all over the world registered at the EULAR Congress 2011 in London, this year’s London Congress is hoping to surpass all previous records.

read more »

Maximising uptake of biosimilars in an evolving market

Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.

 

read more »